The IAO team of Amsterdam Neuroscience & Brain Center Rudolf Magnus attended the Bio International Convention from 18-22 June in San Diego. At this meeting with 16000+ attendees from 76 countries they met up with over 45 different biotech- and pharma-companies to discuss the complex range of to be acquired contract-research projects, and collaborations in which our clinicians give guidance in clinical trials and other types of collaborations between Amsterdam Neuroscience & Brain Center Rudolf Magnus and external industrial stakeholders and putative sponsors. The business development team of the IAO currently includes (from left to right): Pieter van Bokhoven, Christian Gonzalez, Sanne Stembert, Khanum Ridler and Tim Moser:
Pieter van Bokhoven: “Talking to these companies also allowed us to do trend watching on drug development for CNS disorders. This year we observed an increasing number of small biotechnology companies working on therapies for Parkinson’s disease that go beyond α-synuclein as a target. Also, FDA-approved drugs are being repurposed in clinical trials for mood disorders; in patient populations that are better stratified based on clinical and biomarker profiles. Finally, and interestingly, we found the first ‘Tech’ companies making steps towards therapeutic interventions. An example is Calico, a Google subsidiary, developing drugs for age-related diseases such as dementia in collaboration with AbbVie.”
The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.